key: cord-0776256-425578of authors: Imaduddin, Mohammed; Sultania, Mahesh; Vigneshwaran, B; Kumar Muduly, Dillip; Kar, Madhabananda title: Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer Patients During COVID-19 Pandemic date: 2020-10-24 journal: Oral Oncol DOI: 10.1016/j.oraloncology.2020.105069 sha: d8ee343e240521a120307c4994e3e6f45dc63d4f doc_id: 776256 cord_uid: 425578of • Metronomic Therapy - Advantage of ease of administration, safety, and compliance. • We have successfully avoided disease progression in resectable disease. • During COVID-19 pandemic, metronomic therapy is a boon in oral cancer patients. Patients with resectable cancer were counseled for the need for surgery, the pandemic related risks, and to be on the waiting list with an option to take metronomic therapy as a bridge to tide over the COVID pandemic time. Patients with unresectable/inoperable cancer were counseled regarding the prognosis of the disease and the role of chemoradiation and conventional chemotherapy regimens. They were offered metronomic therapy with a palliative intent if not willing for conventional treatment. After informed consent, metronomic therapy started consisted of oral methotrexate 15 mg/m 2 once a week and oral celecoxib 200 mg twice daily. The patients were followed every two weeks, either by teleconsultation using video calls or by out-patient visits, to assess the disease status and response to therapy. The response was during the follow-up period (13.3%) and were managed with home isolation. [ Table 1 ] Due to the inability to provide definitive management, the intention of therapy was to prevent the progression of disease during this period. Of the 15 patients, 11 patients had potentially curable oral cavity cancers, and four patients required palliative therapy. Except for the one patient with advanced unresectable oral cancer who expired, the rest of the patients in the study had either partial response or stable disease. No disease progression was seen. Several authors have suggested guidelines in the past few months to provide optimal care to cancer patients [4, 5] . Also, oral cancer surgeries are significant aerosol-generating procedures and put the operating team at a significant risk of acquiring the infection. The viral load in asymptomatic patients is similar to symptomatic patients, suggesting the transmission potential of asymptomatic patients In the present study, we have been successful in avoiding disease progression in resectable disease. In our experience, to manage oral cancers during the ongoing COVID-19 pandemic, metronomic therapy is beneficial. We eagerly await the restoration of health services in the region and provide surgical treatment to resectable patients. Worldometer -real time world statistics What is the best treatment option for head and neck cancers in COVID-19 pandemic? A rapid review Epub ahead of print Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis Recommendations for head and neck surgical oncology practice in a setting of acute severe resource constraint during the COVID-19 pandemic: an international consensus COVID-19 and head and neck cancer treatment SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients Proportion of asymptomatic coronavirus disease 2019: A systematic review and meta-analysis False-negative results of initial RT-PCR assays for covid-19: a systematic review Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study Erratum in: Lancet Primary chemotherapy in resectable oral cavity squamous cell cancer: a randomized controlled trial Long-term results of a randomized phase III trial of TPF induction chemotherapy followed by surgery and radiation in locally advanced oral squamous cell carcinoma Oral Cancer Surgery and COVID pandemic -Metronomic Therapy shows a promising role while awaiting surgery Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial. Lancet Glob Health Clinically partial response with metronomic therapy after 14 weeks. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.